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OBJECTIVES: To perform a systematic review and meta-analysis of all randomized
controlled trials comparing efficacy of Intermittent versus continuous chemother-
apy (CT) for first-line treatment of unresectable Metastatic Colorectal Cancer
(CCRm). METHODS: Several databases were searched, including MEDLINE, EM-
BASE, LILACS, and CENTRAL. The primary endpoint was overall survival (OS). The
data extracted from the studies were combined by using Hazard Ratio (HR) with
their corresponding 95% confidence intervals (CI95%). RESULTS: Overall, 733 refer-
ences were identified and screened. The final analysis included 4 trials comprising
1,827 patients analyzed. There was no statistically significant difference between
the groups (Intermittent vs continuous chemotherapy) on the analysis of overall
survival (fixed effect: HR1.03, CI95%0.92 to 1.16; p0.56). No heterogeneity was
detected on this analysis (Chi2  2.88, df  3 (P0.41); I2  0%). CONCLUSIONS:
Overall survival was similar between groups. The intermittent chemotherapy reg-
imen provides better quality of life that the scheme is continued and probably cost
saving.
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PRELIMINARY ANALYSIS
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OBJECTIVES: The Human Papillomavirus (HPV) is a known cause of cervical cancer
and genital warts, and causes a proportion of vaginal, vulval, penile, anal, and head
and neck (HN) cancers. Quantifying the broader burden of HPV-related cancers is
important as this group represents approximately 5.2% of all cancers. METHODS:
Using cancer registry data covering the population of England (2003-2008), we ex-
amined incidence of HPV-related cancers. HPV-associated sites were identified
(cervix, vulva, vagina, anus, penis and HN) and grouped according to ICD-O-3 site.
Incidence rates were age-adjusted (ASR) to the European standard population by
the direct method and 95% Confidence intervals (95% CI) calculated using STATA
SE11.0. A literature review was conducted to ascertain the percentage attributable
to HPV for each cancer type. Over 300 articles were reviewed and graded by rele-
vance, sample size, and date.RESULTS:ASRs for HPV-related cancers were: vagina/
vulval cancers: 0.33(95% CI 0.3-0.4) and 1.4(95% CI: 1.3-1.4) per 100,000 females.
Penile cancer: 0.8(95% CI: 0.7-0.8) per 100,000 males. Anal cancers: 10.8(95% CI:10.7-
11.1) males and 6.0(95% CI:5.8-6.0) females per 100,000. Base of tongue and lingual
tonsil: 0.06(95% CI:0.06-0.07) males and 0.02(95% CI:0.01-0.02) females per 100,000;
tonsil: 0.11(95% CI:0.10-0.12) males and 0.03(95% CI:0.03-0.04) females per 100,000;
oropharynx: 0.05(95% CI:0.05-0.06) males and 0.02(95% CI:0.01-0.02) females per
100,000. Estimates reported in literature for percentage of HPV-attributable cases
ranged from 70-100% for cervical, 27-76% vulval, 70-90% vaginal, 40-54% penile,
76-90% anal, and 11-72% for HPV-associated HN cancers. The most commonly
reported strains were HPV 16, 18, 31, and 33. CONCLUSIONS: The incidence of
HPV-related cancers represents a significant burden. Recent incidence estimates
are similar to 2002 estimates, apart from an increase in anal cancers. Estimates of
the HPV-attributable percentage for each cancer and projected prevalence will be
used to assess the impact of implementing a quadrivalent HPV vaccination pro-
gramme in England.
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OBJECTIVES: Metastatic bone lesions lead to an increase in the risk for skeletal
related events (SREs), including pathologic fracture, spinal cord compression, hy-
percalcemia of malignancy, and severe bone pain requiring palliative radiotherapy
or surgery to bone. Twenty-nine percent of breast cancer patients with bone me-
tastases develop SREs. Our objective was to systematically review the literature on
the impact of SREs on pain, quality of life (QOL), morbidity, survival and cost in
breast cancer patients.METHODS:We searched PubMed, limiting to peer-reviewed
English-language human studies published in 2000-2010. The search was based on
a SRE definition accepted by the U.S. Food and Drug Administration and European
Medicines Agency. Articles were included if they were randomized-controlled tri-
als, clinical trials with appropriate control group, systematic reviews, meta-analy-
ses, case-series or economic analyses, and were excluded if they did not provide
interpretable results on outcomes of interest. RESULTS: A total of 209 articles were
screened, of which 131 were excluded, and 78 were abstracted. No studies, outside
of bisphosphonate trials, were identified that examined the impact of SREs as a
group on clinical outcomes. Bisphosphonate treatment reduced SREs, and hence
improved pain and QOL. Literature indicated that presence of pathologic bone
fractures is correlated with increased risk of death. Spinal cord compression sig-
nificantly impaired ambulatory function and shortened survival of these patients
compared to historical controls. Radiation therapy improved pain and QOL while
bone surgery was shown to improve pain and function with vertebrectomy. Lim-
ited evidence suggested treatment cost of SREs is $14,000 (95% CI: $11,000-$17,000)
per patient. CONCLUSIONS: Presence of clinical SREs is associated with worse
morbidity and survival, while their treatment is associated with improved pain,
QOL and morbidity among breast cancer patients. SREs appear to increase cost of
treatment substantially.
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OBJECTIVES: Between 65-75% of patients with prostate cancer experience meta-
static bone disease. Metastatic bone lesions increase risk for skeletal related events
(SREs), which include clinical SREs (pathologic fracture, spinal cord compression,
hypercalcemia of malignancy) and treatments of clinical SREs (radiotherapy or
surgery to bone) resulting from severe bone pain. Our objective was to systemati-
cally review the literature on the impact of SREs on pain, quality of life (QOL),
morbidity, survival and cost in prostate cancer patients. METHODS: We searched
PubMed, limiting to peer-reviewed English-language human studies published in
2000-2010. The search was based on SRE definition accepted by the US Food and
Drug Administration and European Medicines Agency. Articles were included if
they were randomized-controlled trials, clinical trials with appropriate control
group, systematic reviews, meta-analyses, case-series or economic analyses, and
were excluded if they did not provide interpretable results on outcomes of interest.
RESULTS:A total of 209 articles were screened, of which 131 were excluded, and 78
were abstracted. No studies, outside of bisphosphonate trials, were identified that
examined the impact of SREs as a group on clinical outcomes. In bisphosphonate
trials, patients with SREs had significantly more pain and worse 1-year survival
compared with no SREs. Pathologic bone fractures significantly decreased QOL and
were associated with increased risk of death. Although spinal cord compression
(SCC) has a significant impact on pain, improvement in morbidity may be achieved
if SCC is treated. SCC is associated with significant decreases in patient survival.
Radiation therapy improved pain and possibly QOL while bone surgery improved
pain. Limited evidence suggested SREs increased cost by approximately €7,000
(Euros) and $12,000 (USD). CONCLUSIONS: Clinical SREs are associated with worse
clinical outcomes, including pain, QOL, morbidity and survival, while treatment of
clinical SREs is associated with improved pain and QOL among prostate cancer
patients. SREs appear to increase cost substantially.
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OBJECTIVES: To assess the overall risk of bevacizumab related adverse events in
patients with metastatic colorectal cancer (mCRC).METHODS:A systematic review
of the literature was conducted. The selection criteria of the studies for this review
were: health technology agencies reports, meta-analysis, systematic reviews, ran-
domized controlled trials (RCTs) and observational studies in patients treated with
bevacizumab for mCRC. MEDLINE, EMBASE, the Cochrane Library, and CRD data-
bases were searched until June 8, 2011. The selection of the studies, quality assess-
ment, data extraction and data analysis were done independently by two authors.
Disagreements were resolved by a third reviewer until consensus was obtained.
RESULTS: To evaluate the safety profile of bevacizumab, two systematic reviews
with meta-analysis and two observational studies were included (the BEAT and the
BRiTE studies). A total of 3271 patients were included in one meta-analysis, which
evaluated the risk of fatal adverse events (FAE) and 3,385 patients were included in
the other meta-analysis, which evaluated any grade of toxicity. An increased risk of
FAE was not observed between patients with mCRC receiving bevacizumab in com-
bination with chemotherapy and patients receiving chemotherapy alone [Relative
Risk (RR):1.21 Confidence Interval (CI) 95%: 0.65-2.24]. Patients treated with bevaci-
zumab had an increased risk of developing grade 3-4 hypertension (RR: 4.27; CI95%:
2.80–6.51), any grade gastrointestinal perforation (RR: 5.04; CI95%: 1.72–14.79),
grade 3-4 arterial thromboembolic events (RR: 1.23; CI95%: 0.93–1.62), and discon-
tinuation because of grade 3-4 adverse events (RR: 1.21; CI95%: 1.03–1.43). The
results from the observational studies were consistent with the data reported in
the meta-analysis. CONCLUSIONS: Although the risk of FAE was not increased
with bevacizumab in patients with mCRC, grade 3-4 hypertension, any grade gas-
trointestinal perforation, grade 3-4 arterial thromboembolic events, and discontin-
uation due to grade 3-4 adverse events were higher in the bevacizumab group.
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OBJECTIVES: An interim analysis of APEX, a phase III randomized, open-label clin-
ical trial, demonstrated superiority of bortezomib over high-dose dexamethasone
in terms of time to disease progression (TTP). According to the original study pro-
tocol, patients were allowed to cross over on disease progression. Following in-
terim analysis, patients could cross over regardless of the disease status. The ITT
analysis of overall survival (OS) may therefore result in a biased estimate of the
treatment effect. This study aimed to adjust the analysis for crossover. METHODS:
The Iterative Parameter Estimation (IPE) algorithm using a Weibull distribution was
selected as the primary analysis based on the findings from a simulation study
(Morden et al). The IPE algorithm using a Gompertz distribution and the Rank
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